Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

32.52
-1.7300-5.05%
Post-market: 32.19-0.3300-1.01%19:57 EDT
Volume:2.25M
Turnover:73.93M
Market Cap:3.76B
PE:-10.19
High:34.25
Open:33.99
Low:32.30
Close:34.25
52wk High:43.15
52wk Low:18.92
Shares:115.55M
Float Shares:110.00M
Volume Ratio:0.90
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1920
EPS(LYR):-3.1920
ROE:-47.34%
ROA:-30.27%
PB:5.88
PE(LYR):-10.19

Loading ...

Viking Therapeutics Stock Soars: What's Driving The Momentum?

Benzinga
·
Feb 13

Jefferies Keeps Their Buy Rating on Viking Therapeutics (VKTX)

TIPRANKS
·
Feb 12

Maxim Group Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

TIPRANKS
·
Feb 12

BUZZ-U.S. STOCKS ON THE MOVE-PPG Industries, American Electric Power, West Pharmaceutical

Reuters
·
Feb 12

Viking Therapeutics (VKTX) Gets a Buy from Piper Sandler

TIPRANKS
·
Feb 12

BUZZ-U.S. STOCKS ON THE MOVE-Cisco Systems, Viking Therapeutics, Albemarle

Reuters
·
Feb 12

Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating

MT Newswires Live
·
Feb 12

Viking Therapeutics Shares up 11.7% Premarket as Co Plans to Advance Oral Obesity Drug to Late-Stage Testing

THOMSON REUTERS
·
Feb 12

Viking Therapeutics Plans To Advance Oral Obesity Drug To Late-Stage Testing

Reuters
·
Feb 12

Stock Track | Viking Therapeutics Soars 12.26% in Pre-Market on Positive Obesity Drug Pipeline Updates

Stock Track
·
Feb 12

Stock Track | Viking Therapeutics Soars 9.91% in Post-Market on Positive Pipeline Updates Despite Earnings Miss

Stock Track
·
Feb 12

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), CSL (CMXHF)

TIPRANKS
·
Feb 12

BUZZ-Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies

Reuters
·
Feb 12

Stock Track | Viking Therapeutics Soars 8.30% After-Hours Despite Earnings Miss on Positive Pipeline Updates

Stock Track
·
Feb 12

Viking Therapeutics Inc - Oral Vk2735 to Enter Phase 3 Trials for Obesity in 3Q26

THOMSON REUTERS
·
Feb 12

Viking Therapeutics Q4 Operating Expenses USD 164.738 Million

THOMSON REUTERS
·
Feb 12

Press Release: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Feb 12

Viking Therapeutics posts Q4 net loss of USD 157.7 million, over quadruple increase

Reuters
·
Feb 12

Viking Therapeutics options imply 9.5% move in share price post-earnings

TIPRANKS
·
Feb 12

Viking Therapeutics Inc. published an update to their financial calendar

Reuters
·
Feb 05